4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR.
4,5-Disubstituted cis-pyrrolidinones were investigated as inhibitors of type II 17beta-hydroxysteroid dehydrogenase (17beta-HSD). Early structure-activity relationship patterns for this class of compounds are discussed.
Gunn
David
D
Bayer Research Center, Bayer HealthCare Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516, USA. david.gunn.b@bayer.com
Akuche
Christiana
C
Baryza
Jeremy
J
Blue
Marie-Louise
ML
Brennan
Catherine
C
Campbell
Ann-Marie
AM
Choi
Soongyu
S
Cook
James
J
Conrad
Patricia
P
Dixon
Brian
B
Dumas
Jacques
J
Ehrlich
Paul
P
Gane
Todd
T
Joe
Ted
T
Johnson
Jeffrey
J
Jordan
Jerold
J
Kramss
Richard
R
Liu
Peying
P
Levy
Joan
J
Lowe
Derek
D
McAlexander
Ian
I
Natero
Reina
R
Redman
Anikó M
AM
Scott
William
W
Seng
Thomas
T
Sibley
Robert
R
Wang
Ming
M
Wang
Yamin
Y
Wood
Jill
J
Zhang
Zhonghua
Z
D015067:17-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D011760:Pyrrolidinones / Q000737:chemistry / Q000494:pharmacology*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D004791:Enzyme Inhibitors; D011760:Pyrrolidinones; D015067:17-Hydroxysteroid Dehydrogenases; C044256:3 (or 17)-beta-hydroxysteroid dehydrogenase